Key facts
- Wells Fargo upgraded Tandem Diabetes to overweight.
- Wells Fargo maintained an equal-weight rating.
- The firm raised its price target on the stock to $55 from $45.
Analyst upgrades and target price changes can significantly influence investor sentiment and stock performance, particularly for companies in growth sectors like medical technology.